Literature DB >> 18718483

Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine].

Jesse A May1, Najam A Sharif, Hwang-Hsing Chen, John C Liao, Curtis R Kelly, Richard A Glennon, Richard Young, Jun-Xu Li, Kenner C Rice, Charles P France.   

Abstract

AL-38022A is a novel synthetic serotonergic (5-HT) ligand that exhibited high affinity for each of the 5-HT2 receptor subtypes (Ki<or=2.2 nM), but a significantly lower (>100-fold less) affinity for other 5-HT receptors. In addition, AL-38022A displayed a very low affinity for a broad array of other receptors, neurotransmitter transport sites, ion channels, and second messenger elements, making it a relatively selective agent. AL-38022A potently stimulated functional responses via native and cloned rat (EC50 range: 1.9-22.5 nM) and human (EC50 range: 0.5-2.2 nM) 5-HT2 receptor subtypes including [Ca2+]i mobilization and tissue contractions with apparently similar potencies and intrinsic activities and was a full agonist at all 5-HT2 receptor subtypes. The CNS activity of AL-38022A was assessed by evaluating its discriminative stimulus effects in both a rat and a monkey drug discrimination paradigm using DOM as the training drug. AL-38022A fully generalized to the DOM stimulus in each of these studies; in monkeys MDL 100907 antagonized both DOM and AL-38022A. The pharmacological profile of AL-38022A suggests that it could be a useful tool in defining 5-HT2 receptor signaling and receptor characterization where 5-HT may function as a neurotransmitter.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718483      PMCID: PMC3763814          DOI: 10.1016/j.pbb.2008.07.015

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.697


  35 in total

1.  Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor.

Authors:  P Ghanouni; J J Steenhuis; D L Farrens; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists.

Authors:  Gayathri Swaminath; Xavier Deupi; Tae Weon Lee; Wen Zhu; Foon Sun Thian; Tong Sun Kobilka; Brian Kobilka
Journal:  J Biol Chem       Date:  2005-04-07       Impact factor: 5.157

3.  Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy.

Authors:  Barbara J Ebersole; Irache Visiers; Harel Weinstein; Stuart C Sealfon
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

Review 4.  Discriminative stimulus properties of amphetamine and structurally related phenalkylamines.

Authors:  R Young; R A Glennon
Journal:  Med Res Rev       Date:  1986 Jan-Mar       Impact factor: 12.944

5.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Authors:  R R Griffiths; W A Richards; U McCann; R Jesse
Journal:  Psychopharmacology (Berl)       Date:  2006-07-07       Impact factor: 4.530

6.  Beta-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane.

Authors:  Richard A Glennon; Mikhail L Bondarev; Nantaka Khorana; Richard Young; Jesse A May; Mark R Hellberg; Marsha A McLaughlin; Najam A Sharif
Journal:  J Med Chem       Date:  2004-11-18       Impact factor: 7.446

7.  Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys.

Authors:  Jun-Xu Li; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2007-11-09       Impact factor: 4.030

8.  Cloned human 5-HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation.

Authors:  Najam A Sharif; Colene D Drace; Gary W Williams; Julie Y Crider
Journal:  J Pharm Pharmacol       Date:  2004-10       Impact factor: 3.765

9.  Mechanistic studies on DOM as a discriminative stimulus.

Authors:  R A Glennon; A E Hauck
Journal:  Pharmacol Biochem Behav       Date:  1985-12       Impact factor: 3.533

10.  Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity.

Authors:  P M Sweetnam; J Lancaster; A Snowman; J L Collins; S Perschke; C Bauer; J Ferkany
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

View more
  5 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

3.  The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.

Authors:  Richard A Glennon
Journal:  J Med Chem       Date:  2017-03-15       Impact factor: 7.446

4.  Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

Authors:  Clinton E Canal
Journal:  Handb Exp Pharmacol       Date:  2018

Review 5.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.